Global Diabetic Neuropathy Market 2014-2018

Price :
Published : May-2014
No. of Pages : 55

Report Description

Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.

TechNavio’s analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Diabetic Neuropathy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various pain management drugs administered to relieve the pain symptoms associated with diabetic neuropathy. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Diabetic Neuropathy market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, the Global Diabetic Neuropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Neuropathy market landscape and its growth prospects in the coming years.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Eli Lilly and Co.
  • Janssen Pharmaceuticals Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • Actavis plc
  • Cephalon Inc.
  • MEDA Pharma GmbH & Co. KG

Key Market Driver

  • Increasing Global Diabetic Population.
  • For a full, detailed list, view our report.

Key Market Challenge

  • High Failure Rate in Clinical Trials.
  • For a full, detailed list, view our report.

Key Market Trend

  • Increasing R&D Activities.
  • For a full, detailed list, view our report.

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05. Introduction

06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis

07. Geographical Segmentation

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Market Share Analysis 2013
15.3 Other Prominent Vendors

16. Key Vendor Analysis
16.1 Pfizer Inc.
16.1.1 Business Overview
16.1.2 Key Information
16.1.3 SWOT Analysis
16.2 Eli Lilly and Company
16.2.1 Business Overview
16.2.2 Business Segmentation
16.2.3 Key Information
16.2.4 SWOT Analysis
16.3 Janssen Pharmaceuticals Inc.
16.3.1 Business Overview
16.3.2 Key Information
16.3.3 SWOT Analysis

17. Pipeline Analysis
17.1 Phase III Analysis
17.2 Phase II Analysis
17.3 Phase I Analysis
17.4 Discontinued Projects
17.5 Projects on Hold
17.6 Promising Pipeline Molecules
17.6.1 Phase III Promising Pipeline Molecules
17.6.2 Phase II Promising Pipeline Molecules
17.7 Other First-in-class Pipeline Molecules:

18. Other Reports in this Series

List of Exhibits:

Exhibit 1: Market Research Methodology
Exhibit 2: Global Diabetic Neuropathy Market 2013-2018 (US$ billion)
Exhibit 3: Global Diabetic Neuropathy Market by Geographical Segmentation 2013
Exhibit 4: Eli Lilly and Company: Business Segmentation
Exhibit 5: Diabetic Neuropathy Pipeline Snapshot 2013
Exhibit 6: Discontinued Pipeline Molecules on the basis of MOA

Filed in: Pharmaceutical, Therapeutics
Publisher : Infiniti Research Limited
More Reports
Title Price Buy Now

Global Anti-Obesity Drugs Market 2015-2019

Obesity is a medical condition in which there is surplus accumulation of fat in the body. It is linked with increased illness risk, disability, and death. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure. TechNavio's analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 39.45 percent over the period 2014-2019. Covered in this Report The Global Anti-obesity Drugs market can be divided into two segments: Peripherally Acting Anti-obesity Drugs and Centrally Acting Anti-obesity Drugs. This report covers the present scenario and the growth prospects of the Global Anti-obesity Drugs market for the period 2014-2019. To calculate the market size, the report considers the revenue generated f......
$2500

Global Lung Cancer Therapeutics Market 2015-2019

Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Non-small cell lung cancer is the commonest type of lung cancer and forms almost 85-90 percent of the total cases diagnosed. It grows and spreads slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in non-smokers. Non-small cell lung cancer is of three types: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Small cell lung cancers form roughly 10-15 percent of all the diagnosed cases of lung cancer. There are two types of small cell lung cancer: small cell carcinoma and combined small cell carcin......
$3000

Global Oncology Biosimilars Market 2014-2018

Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars. TechNavio's analysts forecast the Global Oncology Biosimilars market to grow at a CAGR of 29.87 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospect......
$2500

Global Irritable Bowel Syndrome Market 2015-2019

Irritable bowel syndrome is a common disorder of the digestive system causing abdominal cramps, discomfort, bloating, constipation, and diarrhea. Inflammatory bowel disease, which is a chronic disease with recurrent immune response and inflammation of the GI tract, is sometimes confused with irritable bowel syndrome. The symptoms of irritable bowel syndrome generally appear in a patient aged around 30 years. According to the CDC, prominent symptoms of irritable bowel syndrome include severe bloating, severe stomach cramps or abdominal pain, lower back pain, groin pain, heartburn, acidity, shooting pain in the legs, and lightheadedness after eating. TechNavio's analysts forecast the Global Irritable Bowel Syndrome market to grow at a CAGR of 14.04 percent over the period 2014-2019. Co......
$2500

Global Schizophrenia Therapeutics Market 2014-2018

Schizophrenia is a chronic brain disorder that severely affects the quality of life of a patient by disturbing the normal functioning of the brain. Psychotic symptoms and a diminished range of expression of emotions are the characteristics of schizophrenia. The exact etiology of schizophrenia is still not known. In men, it appears in the late teens or early 20s, and in women in the late 20s or early 30s. However, most of the symptoms of this disorder can be managed with medication and psychological help. TechNavio's analysts forecast the Global Schizophrenia Therapeutics market to grow at a CAGR of 2.82 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospects of the Global Schizophrenia Therapeutics market for the p......
$3000

Global Pulmonary Drug Delivery Systems Market 2015-2019

Pulmonary delivery of drugs leads to the deposition of drugs in the lungs and subsequent local or systemic therapeutic activity. The pulmonary route of administration for the non-invasive delivery of drugs is mostly preferred because of the large surface area for absorption, high blood circulation, and high permeability rate. Pulmonary drug delivery offers various advantages over peroral routes, such as bypass of hepatic first-pass metabolism, quick onset of action, and low enzymatic activity. Pulmonary delivery of drugs can be achieved by intranasal administration or oral inhalative administration, the latter being more effective. Oral inhalative administration includes intratracheal inhalation and intratracheal instillation. Oral inhalation delivers the aerosolized drug using devices suc......
$3000

Medical Technology Market in Europe 2014-2018

Medical technology refers to technology used in individuals suffering from wide range of conditions to ensure better health of the patients. It involves the entire pathway from diagnosis to cure of the patient. The medical technologies bring healthy life years, prevents disease progression, and show a vital role in healthcare. The Medical technology includes: software solutions, medical devices, imaging, biological derived devices, and diagnostic equipment; technologies such as active and non-active implantable, aesthetic and respiratory, IVD, dental, electromechanical medical, and therapeutic radiation. Many people depend on medical technology at home, hospital and nursing homes for life-supporting machines, wheelchairs, insulin pens, pregnancy tests: more than five million medtech produc......
$2500

Global Dialysis Services Market 2015-2019

A kidney is an essential organ of the body that excretes waste, salt, and excess water from the body. Kidney failure or an injury to the kidneys can cause serious problems such as a blood clot, infection, and multiple myelomas. Dialysis is a treatment that works like an artificial kidney by eliminating waste and excess water from the body. During dialysis, the blood of an individual is cleaned by the removal of excess waste such as creatinine and nitrogen that builds up in the bloodstream. Dialysis is done with the help of a dialysate fluid. Dialysate is a mixture of chemicals and pure water that helps remove waste from the blood without removing the substances that the body needs. TechNavio's analysts forecast the Global Dialysis Services market to grow at a CAGR of 4.65percent over th......
$2500

Global Cushing’s Syndrome Therapeutics Market 2015-2019

Cushing's syndrome is a condition caused by the prolonged exposure to very high levels of cortisol. This can occur because of the consumption of glucocorticoid drugs or diseases that result in excess cortisol, ACTH, and CRH secretion. Harvey Cushing described the pathophysiology of this condition in 1932. It is more common in women than in men. Cushing's syndrome is also known as hypercortisolism, hypercorticism, hyperadrenocorticism, or Itsenko-Cushing syndrome. Some of the common symptoms of Cushing's syndrome are increase in weight, facial acne, cognitive disorders, and vulnerability to superficial fungus infections, growth of a mass around the collarbone or back of the neck, commonly known as the "buffalo hump," and puffy face or "moon face". Other symptoms include sweating, polyuria, ......
$2500

Global Cardiovascular Information System Market 2015-2019

A CVIS is a collection of research and clinical data gathered with the help of unique software, which facilitates information and support, and provides a complete medical record of patients in the cardiovascular field. The CVIS is used to endorse data with a high level of evidence-based quality. The CVIS improves patient safety and provides quality care by eliminating duplicate entries and reducing errors, besides improving efficiency. The productivity of the CVIS is high as it has access to all the cardiac images of a patient from anywhere along with relevant information of that cardiac patient. The CVIS finds application in the following fields: echocardiography, electrocardiography, electrophysiology, catheterization labs, and other CVIS solutions such as cardiac CT/MRI, hemodynamics, a......
$2500